Jazz Pharmaceuticals’ Epidiolex shows efficacy in epilepsy presentations

Jazz Pharmaceuticals will present eight abstracts at the 15th European Epilepsy Congress. Results showed most caregivers reported patient improvements in seizure and non-seizure outcomes since initiating Epidyolex. In addition, post-hoc analyses of pooled data from 215 participants from the GWPCARE3 and GWPCARE4 Epidyolex Phase 3 trials will be presented, demonstrating thresholds for clinically meaningful reductions in drop seizures in patients with LGS. Results from the BECOME subgroup analysis indicating that treatment with Epidyolex and concomitant clobazam, in both pediatric and adult patients with LGS or DS, led to caregiver-reported improvements in both seizure frequency – 87% -, seizure severity – 81% – and weekly seizure-free days – 68% -. Results reported improvements in at least one item for non-seizure-related domains. 94% of the 243 caregivers surveyed indicated they planned to continue with Epidyolex treatment. Results from a post-hoc analysis of data from pivotal trials GWPCARE3 and GWPCARE4, in patients with LGS who received Epidyolex for 14 weeks showed that of 215 patients analyzed, 67 reported a ‘much improved or better’ CGIC score and 129 reported a ‘slightly improved or better’ CGIC score. For those receiving concomitant clobazam, CIR thresholds were relatively consistent between subgroups and the overall population.